SecBot SecBot

HMDCF

HUTCHMED (China) Ltd
OTC· Pharmaceutical Preparations· Inc. E9· CIK 0001648257 Biotech & Drug Discovery
$2.16 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $2.16
1 year
−41.0%
from $3.66 · Oct 27
30 days
0.0%
from $2.16
52-week range
$2.16–3.66
−41% from high · low May 20
Avg volume 20D
0
Sep 28 spike 0
Short interest
🔒 Subscribers only
Filing reports
5
analyzed by SecBot
SecBot read BULLISH 5 reports · latest
Balance 0 bearish · 2 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/5
Strongest BULLISH HUTCHMED and Innovent announced NMPA approval for ELUNATE (fruquintinib) in combination with TYVYT…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • TrendRANGE

    0% above its 50-day average. New closing low $2.16 on Oct 23.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 Clinical trial readout
Results Pending: fruquintinib+sintilimab (Phase 3) — Completed 53d ago
Trial: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Car
May 21, 2026 SEC
HUTCHMED and Innovent announced NMPA approval for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab) for…
6-K — Impact 7/10
May 12, 2026 SEC
HUTCHMED reported that all resolutions at its May 12, 2026 Annual General Meeting were passed, including re-election…
6-K — Impact 1/10
Apr 29, 2026 SEC
HUTCHMED announced that its NDA for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) was accepted for…
6-K — Impact 7/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 20, 2026
Trial readout
Results Pending: fruquintinib+sintilimab (Phase 3) — Completed 53d ago
Trial: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) Sponsor: Hutchmed Phase…
Sep 24, 2026
Clinical Trial
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Phase 2 · COMPLETED
May 4, 2026
Clinical Trial
Phase III Study on HMPL-523 for Treatment of ITP
Phase 3 · COMPLETED

SecBot reports

5 filings · 2 bullish · 0 bearish · 3 neutral
All HMDCF filing & press-release reports (5)